JP2022527084A5 - - Google Patents

Info

Publication number
JP2022527084A5
JP2022527084A5 JP2021557383A JP2021557383A JP2022527084A5 JP 2022527084 A5 JP2022527084 A5 JP 2022527084A5 JP 2021557383 A JP2021557383 A JP 2021557383A JP 2021557383 A JP2021557383 A JP 2021557383A JP 2022527084 A5 JP2022527084 A5 JP 2022527084A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527084A (ja
JP7555953B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025181 external-priority patent/WO2020205499A1/en
Publication of JP2022527084A publication Critical patent/JP2022527084A/ja
Publication of JP2022527084A5 publication Critical patent/JP2022527084A5/ja
Application granted granted Critical
Publication of JP7555953B2 publication Critical patent/JP7555953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557383A 2019-03-29 2020-03-27 Cd38に結合する操作されたバリアント抗体 Active JP7555953B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825983P 2019-03-29 2019-03-29
US62/825,983 2019-03-29
PCT/US2020/025181 WO2020205499A1 (en) 2019-03-29 2020-03-27 Engineered variant antibodies that bind cd38

Publications (3)

Publication Number Publication Date
JP2022527084A JP2022527084A (ja) 2022-05-30
JP2022527084A5 true JP2022527084A5 (cg-RX-API-DMAC7.html) 2023-02-16
JP7555953B2 JP7555953B2 (ja) 2024-09-25

Family

ID=72666916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557383A Active JP7555953B2 (ja) 2019-03-29 2020-03-27 Cd38に結合する操作されたバリアント抗体

Country Status (6)

Country Link
US (1) US20220144966A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947465A4 (cg-RX-API-DMAC7.html)
JP (1) JP7555953B2 (cg-RX-API-DMAC7.html)
CN (2) CN114524877A (cg-RX-API-DMAC7.html)
CA (1) CA3134612A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020205499A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7637510B2 (ja) * 2018-06-20 2025-02-28 ビバソル, インコーポレイテッド Cd38に結合するバリアント抗体
CN114516918B (zh) * 2022-03-04 2022-09-27 四川大学华西医院 一种抗体及其应用
CN114409788B (zh) * 2022-03-04 2022-10-04 四川大学华西医院 抗cd38的抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN120607617A (zh) * 2024-03-07 2025-09-09 宜明昂科生物医药技术(上海)股份有限公司 靶向cd38和cd47的重组融合蛋白

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413737B2 (en) * 2003-11-14 2008-08-19 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201503812D0 (en) * 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
CN113527495A (zh) * 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
CA3002609C (en) * 2015-11-17 2023-09-05 Global Bioenergies Methods for producing isobutene from 3-methylcrotonic acid
KR102770106B1 (ko) * 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
JP7359700B2 (ja) 2017-06-20 2023-10-11 ソレント・セラピューティクス・インコーポレイテッド Cd38抗体薬物コンジュゲート
JP7637510B2 (ja) * 2018-06-20 2025-02-28 ビバソル, インコーポレイテッド Cd38に結合するバリアント抗体

Similar Documents

Publication Publication Date Title
JP7273101B2 (ja) Cd38に結合する抗体治療剤
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
JP2022521956A5 (cg-RX-API-DMAC7.html)
CN111670203B (zh) 双特异性抗体
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
WO2018113258A1 (zh) 抗pd-1抗体及其用途
CN107922484A (zh) 结合tim3的抗体治疗剂
TW202146451A (zh) 抗人類cd19抗體
JP2023179541A (ja) Cd3結合分子
JP7688805B2 (ja) 二重特異性抗体
JP2022120846A (ja) ヒトpd-l1に結合する抗体
US20250206820A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
JP2023532248A (ja) 免疫関連疾患のためのtigitに対するヒトモノクローナル抗体
JP7574692B2 (ja) 二重特異性抗体
AU2020272376B2 (en) Bispecific antibody specifically binding to GPNMB and CD3, and use thereof
RU2021128015A (ru) Антигенсвязывающие белки, которые связываются с bcma
US20250376531A9 (en) Anti-4-1bb antibodies and methods of making and using thereof
JP7714992B2 (ja) 二重特異性抗体を有効成分として含む医薬組成物
WO2019072274A1 (zh) 一种激动型4-1bb单克隆抗体
KR20260062933A (ko) 항-γδ TCR 항체 및 이의 용도
HK40062297A (en) Bispecific antibody
HK40062297B (en) Bispecific antibody
HK1253584B (en) Antibody therapeutics that bind cd38